Abstract
In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Botulinum Toxins / immunology*
-
Botulinum Toxins / therapeutic use*
-
Botulinum Toxins, Type A
-
Drug Resistance / drug effects
-
Drug Resistance / immunology*
-
Female
-
Humans
-
Male
-
Middle Aged
-
Neuromuscular Agents / immunology
-
Neuromuscular Agents / therapeutic use
-
Torticollis / drug therapy*
-
Torticollis / immunology*
-
United States
Substances
-
Neuromuscular Agents
-
rimabotulinumtoxinB
-
Botulinum Toxins
-
Botulinum Toxins, Type A